Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

BACKGROUND: Eribulin mesylate is currently indicated as a sequential monotherapy to be administered after two chemotherapeutic regimens, including anthracycline and taxane treatments, for treatment of metastatic breast cancer. This open-label, multicenter phase II study was designed to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashida, Tetsu, Jinno, Hiromitsu, Mori, Katsuaki, Sato, Hiroki, Matsui, Akira, Sakurai, Takashi, Hattori, Hiroaki, Takayama, Shin, Wada, Masahiro, Takahashi, Maiko, Seki, Hirohito, Seki, Tomoko, Nagayama, Aiko, Matsumoto, Akiko, Kitagawa, Yuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027765/
https://www.ncbi.nlm.nih.gov/pubmed/29954362
http://dx.doi.org/10.1186/s12885-018-4628-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027765/
https://www.ncbi.nlm.nih.gov/pubmed/29954362
http://dx.doi.org/10.1186/s12885-018-4628-7

Ejemplares similares